Physician/scientist from the Dana-Farber Cancer Institute and Harvard Medical School Boston, USA. Shom has spurred the development of clinical trials focussing on CDK4/6 inhibitors for HER 2 breast cancers.
Fay joined Breast Cancer Aotearoa Coalition in 2015 because she sees an ongoing need to improve: outcomes for Maori and Pasifika women, access to medicines and medical devices and clinical trials for breast cancer patients in New Zealand.
Irene a recent breast cancer patient of Hauraki, Ngati Raukawa ki te Tonga and Ngāpuhi descent, is passionate about the wellbeing of Māori communities and the care they receive whilst being treated for cancer.
Logan is leading the team at the University of Otago that will aim to exploit a powerful new mRNA in situ hybridisation technology to develop an innovative method for prioritising patients for mutation screening and evaluating genomic sequencing results.